Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database.

被引：0
|
作者：
Shi, Qian
De Gramont, Aimery
Buyse, Marc E.
Grothey, Axel
Schmoll, Hans-Joachim
Seymour, Matthew T.
Adams, Richard A.
Saltz, Leonard
Goldberg, Richard M.
Punt, Cornelis J. A.
Douillard, Jean-Yves
Hecht, J. Randolph
Hurwitz, Herbert
Diaz-Rubio, Eduardo
Porschen, Rainer
Tebbutt, Niall C.
Fuchs, Charles S.
Souglakos, John
Falcone, Alfredo
Sargent, Daniel J.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Hosp St Antoine, Paris, France
[3] Int Inst Drug Dev, Louvain, Belgium
[4] Univ Halle Wittenberg, D-06108 Halle, Germany
[5] Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[6] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA
[9] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[10] ICO Ctr Rene Gauducheau, St Herblain, France
[11] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[12] Duke Univ, Med Ctr, Durham, NC USA
[13] Hosp Clin San Carlos, Madrid, Spain
[14] Klinikum Bremen Ost, Bremen, Germany
[15] Austin Hlth, Heidelberg, Vic, Australia
[16] Univ Melbourne, Heidelberg, Vic, Australia
[17] Dana Farber Canc Inst, Boston, MA 02115 USA
[18] Univ Crete, Sch Med, Iraklion, Greece
[19] Santa Chiara Hosp, Pisa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3533
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Progression-Free Survival (PFS) as a Surrogate for Overall Survival (OS) in Advanced Non-Small Cell Lung Cancer (aNSCLC): Analysis of Patient-Level Pooled Randomized Clinical Trials (RCTs)
    Ports, Kayleen
    Chen, Weixi
    Aptekar, Jacob
    Jain, Rahul
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 178 - 178
  • [42] Analysis of the temporal relationship between patient-reported outcomes (PROs) and overall survival (OS) and radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Traina, Shana
    Li, Tracy
    Johnson, Kristen
    Ho, Kai Fai
    Molina, Arturo
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [43] PROGNOSTIC VALUE OF EARLY OBJECTIVE TUMOR RESPONSE (EOTR) TO FIRST LINE SYSTEMIC THERAPY IN METASTATIC COLORECTAL CANCER (MCRC): INDIVIDUAL PATIENT DATA (IPD) META-ANALYSIS OF RANDOMIZED TRIALS FROM THE ARCAD DATABASE
    Sommeijer, Dirkje W.
    Shi, Qian
    Meyer, Jeffrey
    Sjoquist, Katrin M.
    Hoff, Paolo M.
    Seymour, Matthew T.
    Cassidy, Jim
    Goldberg, Richard
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Hurwitz, Herbert
    Tournigand, Christophe
    Tebbutt, Niall C.
    Aranda, Enrique
    Souglakos, John
    Kabbinavar, Fairooz F.
    Chibaudel, Benoist
    De Gramont, Aimery
    Sargent, Daniel J.
    Zalcberg, John
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 76 - 76
  • [44] Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial
    Grothey, A.
    Falcone, A.
    Humblet, Y.
    Bouche, O.
    Mineur, L.
    Adenis, A.
    Tabernero, J.
    Yoshino, T.
    Lenz, H-J.
    Goldberg, R. M.
    Huang, L.
    Wagner, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database.
    Zalcberg, John Raymond
    Shi, Qian
    Ferraro, Danielle Angela
    Meyers, Jeffrey P.
    Saltz, Leonard
    Goldberg, Richard
    Van Cutsem, Eric
    Hurwitz, Herbert
    Fuchs, Charles
    Bokemeyer, Carsten
    Sargent, Daniel J.
    De Gramont, Aimery
    Price, Timothy Jay
    Adams, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months
    Sobrero, A.
    Grothey, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Humblet, Y.
    Bouche, O.
    Mineur, L.
    Barone, C.
    Adenis, A.
    Tabernero, J.
    Yoshino, T.
    Lenz, H.
    Goldberg, R. M.
    Xu, L.
    Wagner, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 40 - 40
  • [47] Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Choueiri, T. K.
    Hessel, C.
    Halabi, S.
    Sanford, B.
    Hahn, O.
    Michaelson, M. D.
    Walsh, M.
    Olencki, T.
    Picus, J.
    Small, E. J.
    Dakhil, S.
    Scheffold, C.
    George, D. J.
    Morris, M. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Impact of molecular markers status on treatment effects comparing EGFR and VEGF monoclonal antibodies (mAbs) in untreated metastatic colorectal cancer (mCRC): Pooled individual patient data (IPD) analysis of randomized trials from the ARCAD database
    Karapetis, C. S.
    Liu, H.
    Sorich, M.
    Fiskum, J.
    Grothey, A.
    Adams, R. A.
    Venook, A.
    Heinemann, V.
    Lenz, H. J.
    Yoshino, T.
    Zalcberg, J. R.
    Chibaudel, B.
    Buyse, M. E.
    De Gramont, A.
    Shi, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S426 - S426
  • [49] Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.
    Grothey, Axel
    Falcone, Alfredo
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Adenis, Antoine
    Tabernero, Josep
    Yoshino, Takayuki
    Lenz, Heinz-Josef
    Goldberg, Richard M.
    Xu, Lei
    Wagner, Andrea
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.
    Grothey, Axel
    Falcone, Alfredo
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Adenis, Antoine
    Tabernero, Josep
    Yoshino, Takayuki
    Lenz, Heinz-Josef
    Goldberg, Richard M.
    Xu, Lei
    Wagner, Andrea
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345